Efficacy and safety of iloprost in patients with septic shock‐induced endotheliopathy—Protocol for the multicenter randomized, placebo‐controlled, blinded, investigator‐initiated trial

Abstract

Background In Europe 700.000 new cases of sepsis occur annually and more than 100.000 of these patients die due to multiorgan failure (MOF). We have identified shock‐induced endotheliopathy (SHINE) to be associated with development of MOF and mortality. Furthermore, in patients with septic shock those with circulating levels of thrombomodulin (TM) above 10 ng/mL have twice the mortality (56% vs 28%) than those with levels below this level. Pilot studies indicate that infusion of iloprost (1 ng/kg/min) is associated with improved endothelial function in patients with septic shock. Material and Methods This is a multicenter, randomized, blinded, investigator‐initiated, adaptive phase 2B trial in up to 384 patients with septic shock‐induced endotheliopathy defined by TM > 10 ng/mL who are allocated 1:1 to 72 hours continuous infusion of iloprost 1 ng/kg/min or placebo (equal volume of saline). The primary outcome is the mean daily modified Sequential Organ Failure Assessment (SOFA) score in the ICU up to day 90. Secondary outcomes include 28‐ and 90‐day all‐cause mortality, days alive without vasopressor in the ICU within 90 days, days alive without mechanical ventilation in the ICU within 90 days, days alive without renal replacement therapy in the ICU within 90 days, numbers of serious adverse reactions, and the number of serious adverse events within the first 7 days. Discussion This trial tests the safety and efficacy of iloprost vs placebo for 72 hours in patients with septic shock and SHINE. The outcome measures focus on the potential effect of the intervention to mitigate organ failure. Trial registration COMBAT‐SHINE trial—EudraCT no. 2019‐001131‐31—Clinicaltrials.gov: NCT04123444—Ethics Committee no. H‐19018258.

Trends in Adaptive Design Methods in Dialysis Clinical Trials: A Systematic Review

“…Phase 2/3 seamless design was the third most common type of adaptive design; 5 trials (8.8%); 1 (3.23%) in dialysis populations and 4 (15.4%) in dialysis outcome trials ( Table 3 83 , 84 , 85 , 86 , 87 , 88 , 89 ). Adaptive dose-escalation, Bayesian adaptive design, and interim analysis were used in 1 trial each.…”

Care Bundles plus Detailed Nursing on Mortality and Nursing Satisfaction of Patients with Septic Shock in ICU

“…Following the release of the international guidelines for the treatment of severe sepsis and septic shock [ 10 , 11 ], the morbidity and mortality rate of severe sepsis have shown a year-on-year decrease. The improvement of adherence to this guideline is an important measure to promote its promotion and improve the prognosis of patients with severe sepsis [ 12 ].…”

“…It proves that care bundles combined with detailed nursing could effectively improve the efficiency of nursing, abate the clinical symptoms of patients, and reduce the mortality rate of patients. Following the release of the international guidelines for the treatment of severe sepsis and septic shock [10,11], the morbidity and mortality rate of severe sepsis have shown a year-on-year decrease.…”

“…Vasoactive drugs were used to maintain the patients' blood pressure, and the corresponding drugs were used for the infected lesion. e patient's medication, vital signs, and organ tissue perfusion were closely monitored [11]. (7) Preventive nursing for complications.…”

Endotheliopathy is associated with slower liberation from mechanical ventilation: a cohort study

“…The trial was underpowered but showed promising results with all point estimates in favor of the Iloprost-treatment. Two other randomized trials testing Iloprost in trauma and septic shock patients with evidence of endotheliopathy are currently ongoing and will provide more evidence if endotheliopathy is indeed a modifiable pathology or not [ 37 , 38 ].…”